Press release
Navigating the Future: Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Trends and Forecast Insights, 2025 Edition
Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics
Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market for therapeutics of castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) has experienced robust growth. The market, which was valued at $7.96 billion in 2024, is forecasted to increase to $8.43 billion in 2025, signifying a compound annual growth rate (CAGR) of 5.9%. Factors such as the escalating cases of prostate cancer, extensive usage of androgen deprivation therapy (ADT) leading to resistance, an increase in targeted therapy choices, development in diagnostic imaging facilities, and heightened healthcare investments in the oncology infrastructure have fueled the market's growth during the historic period.
How Will the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Size Evolve and Grow by 2029?
We anticipate significant expansion in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market within the next few years. It is projected to reach $10.48 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.6%. This surge in the forecast period is due to the increased uptake of precision oncology and biomarker-based treatments, escalating demand for advanced hormonal and radioligand therapies, an expanding clinical trials pipeline for advanced prostate cancer, a robust pipeline of targeted and immuno-oncology agents, and a growing requirement for personalized medicine strategies. Forecast period trends encompass the development of combined immunotherapy regimens, the inclusion of genomic profiling in clinical judgement, incorporation of digital health tools for patient surveillance, innovative bispecific T-cell engagers, and the development of tumor microenvironment modulators.
View the full report here:
https://www.thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report
What Drivers Are Propelling the Growth of Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Forward?
The surge in prostate cancer cases is predicted to drive the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market. This cancer type originates in the prostate gland, a minor gland in men situated below the bladder and ahead of the rectum*. The escalation in prostate cancer cases is linked to the aging demographic, since the likelihood of getting prostate cancer considerably surges with age. Therapeutics for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) are pivotal in treating prostate cancer, particularly advanced stages that are impervious to traditional hormone treatment. They boost patient results by decelerating the disease's progression and controlling its symptoms, which in turn improves quality of life. For instance, in November 2024, the National Health Service, a UK government department, reported that new instances of prostate cancer touched a high of 54,732 in 2022, a significant rise of 11,354 cases from 2021. Hence, the escalating cases of prostate cancer are propelling the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp
Which Emerging Trends Are Transforming the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market in 2025?
Prominent businesses in the therapeutics market for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) are prioritizing the development of groundbreaking products and obtaining relevant approvals. This includes the creation of dual-action tablets, cutting-edge formulations that blend two treatment agents in one dose, aiming at multiple routes in CRPC therapy concurrently. As an illustration, in August 2023, the U.S. Food and Drug Administration (FDA) approved Janssen Pharmaceuticals, a pharmaceutical firm from Belgium, for Akeega, an innovative tablet created for adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega, an exactitude medicine, merges a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), focusing on patients with BRCA mutations. Used in combination with prednisone, it substantially boosts radiographic progression-free survival (rPFS) versus traditional hormonal therapy on its own.
What Are the Key Segments in the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market covered in this report is segmented -
1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectable, Intravenous
3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine Therapy, Adoptive Cell Therapy
4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24495&type=smp
Who Are the Key Players Shaping the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market's Competitive Landscape?
Major companies operating in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.
What Geographic Markets Are Powering Growth in the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24495
This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Navigating the Future: Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Trends and Forecast Insights, 2025 Edition here
News-ID: 4092733 • Views: …
More Releases from The Business Research Company
Rise in High-Rise And Supertall Constructions Fueling The Growth Of The Market D …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Building Maintenance Unit (BMU) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The size of the building maintenance unit market has significantly escalated in the past few years. It is projected to increase from $3.16 billion in 2024 to $3.44 billion in 2025, with a…
Future of the Blasting Mats Market: Trends, Innovations, and Key Forecasts Throu …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Blasting Mats Market Size Growth Forecast: What to Expect by 2025?
In recent times, the blasting mats market size has seen robust growth. The market is forecasted to expand from $1.26 billion in 2024 to $1.35 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.3%. This…
Belt Loader Market Expected to Achieve 6.7% CAGR by 2029: Growth Forecast Insigh …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Belt Loader Market Size By 2025?
The market size of belt loader has experienced significant growth in the past few years. The prediction is that it will rise from $1.01 billion in 2024 to $1.08 billion in 2025, registering a compound annual growth rate (CAGR)…
Global Aviation IoT Market Projected to Grow at 20.6% CAGR, Reaching $19.34 Bill …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Aviation IoT Industry Market Size Be by 2025?
In the recent past, the market size of aviation IoT has witnessed massive growth. It is projected that the market will expand from $7.55 billion in 2024 to $9.13 billion in 2025, indicating a compound annual growth rate…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
